Please assess the completion status of the following clinical trial:

Trial Title: Positron Emission Tomography / Magnetic Resonance Imaging (PET/MRI) Guided Biopsy in Men With Elevated PSA

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: DIAGNOSTIC
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Previously undiagnosed patients with elevated PSA (ages 30-50 PSA \>2.5 ng/mL; ages 50-80 PSA \> 4ng/mL), eligible for prostate needle biopsy.~2. Patients can have negative prior needle biopsy(ies) for suspected prostate cancer~3. mpMRI with at least one suspicious target lesion (Arm A), or negative mpMRI but positive biopsy (Arm B).~4. Written informed consent~5. Age \> 30~Exclusion Criteria:~1. Age\> 80~2. Contraindication to MRI or prostate biopsy (e.g. extreme claustrophobia, metallic implants incompatible with MRI, anatomical contraindications, coagulopathy, severe medical comorbidity prohibiting halting of anticoagulation therapies)~3. Active urinary tract infection or indwelling catheter~4. Prior pelvic irradiation~5. Prior prostatectomy~6. Prior androgen deprivation hormonal therapy~7. Prostate biopsy within 8 weeks prior to study~8. Prior transurethral resection of the prostate (TURP)

- Gender: MALE
- Minimum Age: 30 Years
- Maximum Age: 80 Years
- Healthy Volunteers: t

Study Arms:
- PET/MRI before biopsy (Type: EXPERIMENTAL): Patients with suspected areas on mpMRI will undergo additional \[68Ga\]PSMA-11 PET/MRI scan with subsequent mpMRI and PET/MRI guided biopsy.
- PET/MRI after biopsy (Type: EXPERIMENTAL): Patients with unclear areas or a negative finding in the mpMRI for MRI guided biopsy but positive biopsy, which will undergo the additional \[68Ga\]PSMA-11 PET/MRI scan with \[68Ga\]PSMA.

Based on this trial design, predict the completion outcome and termination type (if applicable).